Bayer, Orion Sue Alembic to Block Copies of Nubeqa Cancer Drug

Alembic Pharmaceuticals Ltd.'s proposed copies of the prostate-cancer treatment Nubeqa infringe four patents Orion Corp. licenses to Bayer AG, a federal lawsuit said.

Three Bayer subsidiaries and Orion allege Alembic’s generic 300-milligram tablets of darolutamide, Nubeqa’s active ingredient, infringe US Patent Nos. 10,010,530, 10,383,853, 10,835,515, and 11,168,058, according to a complaint filed July 3 in the US District Court for the District of Delaware.

The patents cover darolutamide and its use for treating non-metastatic castration-resistant prostate cancer, the suit said. The ‘058 patent expires in February 2038, the latest among all but one listed for ...